• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by BGM Group Ltd.

    6/3/25 4:31:34 PM ET
    $BGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGM alert in real time by email
    S-8 1 tm2516603d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 3, 2025

     

    Registration No. 333-

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    BGM Group Ltd

    (Exact Name of Registrant as Specified in Its Charter)

     

    Cayman Islands   Not Applicable
    (State or Other Jurisdiction of   (I.R.S. Employer
    Incorporation or Organization)   Identification No.)

     

    No. 152 Hongliang East 1st Street, No. 1703

    Tianfu New District, Chengdu, 610200

    People’s Republic of China

    Telephone: 86-028-64775180

    (Address, Including Zip Code, of Principal Executive Offices)

     

    BGM Group Ltd

    2025 Equity Incentive Plan

    (Full Title of the Plan)

     

    Puglisi & Associates

    850 Library Avenue, Suite 204

    Newark, DE 19711

    +1 (302) 738-6680

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies To:

     

    Yu Wang, Esq.

    Han Kun Law Offices LLP

    Room 4301-10, 43/F, Gloucester Tower

    The Landmark, 15 Queen’s Road Central

    Hong Kong

    +852-2820-5656

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is being filed by BGM Group Ltd (the “Registrant”) in accordance with the requirements of Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), in order to register 13,000,000 Class A ordinary shares with par value $0.00833335 per share (the “Class A Ordinary Shares”), issuable pursuant to the 2025 Equity Incentive Plan (the “Plan”) adopted by the board of directors (the “Board”) of the Registrant.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information*

     

    Item 2. Registrant Information and Employee Plan Annual Information*

     

    * Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the Note to Part I of Form S-8. The documents containing information specified in this Part I will be separately provided to the participants covered by the Plan, as specified by Rule 428(b)(1) under the Securities Act.

     

    1

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference.

     

    The following documents previously filed or furnished by the Registrant with the Securities and Exchange Commission (“SEC”) are incorporated herein by reference in this Registration Statement:

     

      (a) The Registrant’s Annual Report on Form 20-F for its fiscal year ended September 30, 2024, filed with the SEC on January 27, 2025, as amended by the Amendment No. 1, Amendment No. 2 and Amendment No. 3 to its Annual Report on Form 20-F/A filed with the SEC on February 6, 2025, April 3, 2025 and May 8, 2025 respectively;
         
      (b) The Registrant’s Current Report on Form 6-K, as filed with the SEC on February 28, 2025, March 19, 2025, March 28, 2025, April 22, 2025, April 28, 2025, May 6, 2025, May 20, 2025 and May 28, 2025;
         
      (c) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by its Annual Report referred to in (a) above (other than information deemed to have been “furnished” rather than “filed” in accordance with the SEC’s rules); and
         
      (d) The description of the Company’s Securities contained in the Company’s Annual Report on Form 20-F for its fiscal year ended September 30, 2024, filed with the SEC on January 27, 2025.

     

    Except to the extent such information is deemed furnished and not filed pursuant to the securities laws and regulations, all documents that we file with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act and, to the extent specifically designated therein, reports on Form 6-K furnished by the Registrant to the SEC, in each case, subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement (that indicates that all securities offered under this Registration Statement have been sold or that deregisters all securities then remaining unsold) shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents.

     

    Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

     

    II-1

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Cayman Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.

     

    The Registrant’s third amended and restated memorandum and articles of association provide that its directors and officers shall be indemnified and secured harmless against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such director or officer, other than by reason of such person's own dishonesty in or about the conduct of the Registrant's business or affairs or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil criminal, administrative or investigative proceedings (whether threatened, pending or completed) concerning the Registrant or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.

     

    Pursuant to the indemnification agreements, the form of which was filed as Exhibit 10.3 to the Registrant’s registration statement on Form F-1, as amended (File No. 333-234460), the Registrant has agreed to indemnify its directors and officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such a director or officer.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant pursuant to the foregoing provisions, the Registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    The Exhibits listed on the accompanying Exhibit Index are filed as a part of, or incorporated by reference into, this Registration Statement (See Exhibit Index below).

     

    II-2

     

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of a prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in the post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-3

     

     

    EXHIBIT INDEX

     

    Exhibit    
    Number   Description of Exhibit
    3.1   The Third Amended and Restated Memorandum and Articles of Association (incorporated herein by reference to Exhibit 1.1 to our Current Report on Form 6-K filed with the SEC on October 22, 2024)
         
    4.1   The Description of Securities contained in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024, filed with the SEC on January 27, 2025
         
    5.1*   Opinion of Harney Westwood & Riegels, regarding the legality of the Class A Ordinary Shares being registered
         
    10.1*   2025 Equity Incentive Plan of BGM Group Ltd
         
    23.1*   Consent of ZH CPA, LLC., an independent registered public accounting firm
         
    23.2*   Consent of Enrome LLP, an independent registered public accounting firm
         
    23.3*   Consent of Harney Westwood & Riegels (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included on the signature page to this Registration Statement)
         
    107*   Filing Fee Table

     

    * Filed herewith

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in China on June 3, 2025.

     

      BGM Group Ltd
       
      By: /s/ Chen Xin
      Name: Chen Xin
      Title: Chief Executive Officer and Chairman of the Board of Directors

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Chen Xin as his/her true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him/her and in his/her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on June 3, 2025.

     

    Name   Title
         
    /s/ Chen Xin   Chief Executive Officer and Chairman of the Board of Directors
    Chen Xin   (Principal Executive Officer)
         
    /s/ Yaxuan Zhai   Chief Financial Officer
    Yaxuan Zhai   (Principal Financial and Accounting Officer)
         
    /s/ Waihua Xu   Independent Director
    Waihua Xu    
         
    /s/ Lin Zhang   Independent Director
    Lin Zhang    
         
    /s/ Maofan Tang   Independent Director
    Maofan Tang    
         
    /s/ Furong Cao   Director
    Furong Cao    

     

    II-5

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933 as amended, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement thereto in Newark, Delaware, on June 3, 2025.

     

      Authorized U.S. Representative
       
      Puglisi & Associates
       
      By: /s/ Donald J. Puglisi
      Name: Donald J. Puglisi
      Title: Managing Director

     

    II-6

     

    Get the next $BGM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGM
    Financials

    Live finance-specific insights

    See more
    • From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

      CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

      5/28/25 4:30:00 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Acquires Wonder Dragon to Accelerate "Healthcare" Strategy

      CHENGDU, China, April 21, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) today announced that it has signed a definitive transaction agreement with the existing shareholders of Wonder Dragon Global Limited ("Wonder Dragon"), to acquire 100% of the equity interests of Wonder Dragon by issuing 38,165,290 Class A ordinary shares at a price of $2 per share, for a total transaction valuation of RMB550 million. The transaction is expected to be completed in the second quarter of 2025. Wonder Dragon possesses over 3,000 metric tons of premium Qingzhuan dark tea inventory, comprising 1,670 metric tons of raw materials and 1,350 metric tons of finished products. These premium tea products, known f

      4/21/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Acquires YX to Strengthen AI Strategy for Its Intelligent Platform

      CHENGDU, China, March 19, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM) (NASDAQ:BGM) today announced that it has signed a definitive agreement with the existing shareholders of YX Management Company Ltd. ("YX"), a smart mobility technology company. Under the agreement, BGM will acquire 100% of the equity interests of YX by issuing 47.5 million class A ordinary shares to its existing shareholders, valuing YX at US$95.0 million. This acquisition is based on the exceptional expertise and experience of the YX team in scalable operations, digital infrastructure development, and technology commercialization. The integration of this team will accelerate the AI-driven strategic upgrade

      3/19/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • From Virtual Agents to Embodied and Industry-Specific AI: BGM Acquires Xingdao Intelligent and YD Network, Advancing AI on Two Fronts

      CHENGDU, China, May 28, 2025 /PRNewswire/ -- BGM Group Ltd. (the "Company" or BGM)  (NASDAQ:BGM) today announced that it has entered into definitive transaction agreements with the existing shareholders of Xingdao Intelligent Cloud Chain (Shenzhen) Co., Ltd. ("Xingdao Intelligent") and YD Network Technology Company Limited ("YD Network"). Under the terms of the agreements, BGM will acquire 100% of the equity interests of both companies at a combined valuation of RMB800 million. The consideration will be paid through the issuance of 37,123,142 newly issued Class A ordinary shares of BGM at a price of US$3.0 per share. The transactions are expected to close by the end of June 2025, subject to

      5/28/25 4:30:00 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Announces Strategic Acquisition of HM Management to Expand AI Application Ecosystem

      CHENGDU, China, May 2, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or "BGM") , a leading AI technology company, today announced it has entered into a definitive agreement (the "Agreement") to acquire HM Management Company Limited ("HM Management"), a prominent AI agent production platform, in an all-stock transaction valued at approximately RMB300 million (US$41.7 million). Under the Agreement, BGM will issue 16,663,427 Class A ordinary shares at $2.50 per share to acquire 100% ownership of HM Management and its two wholly-owned subsidiaries: Beijing Shuda Technology Company Limited. ("Shuda Technology") and New Media Star Technology (Shenzhen) Co., Ltd ( "New Media Star

      5/2/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Completes Acquisition of YX to Advance AI-Powered Intelligent Platform

      CHENGDU, China, April 28, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) (the "Company" or BGM)  today announced the completion of its acquisition of YX Management Company Ltd. ("YX"), an leading intelligent mobility technology platform, on April 25, 2025. As previously disclosed, BGM acquired 100% of YX by issuing 47.5 million Class A ordinary shares to YX's existing shareholders, representing a valuation of US$95.0 million. Upon completion of the acquisition, YX's shareholders collectively own approximately 32.6% of BGM's equity interests and approximately 2.2% of the total voting power. This acquisition represents a significant step in BGM's AI-driven transformation, enhancing its capa

      4/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by BGM Group Ltd.

      SC 13D - BGM Group Ltd. (0001779578) (Subject)

      12/3/24 6:03:06 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BGM Group Ltd.

      SC 13D/A - BGM Group Ltd. (0001779578) (Subject)

      11/29/24 9:00:27 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Qilian International Holding Group Ltd.

      SC 13D - Qilian International Holding Group Ltd (0001779578) (Subject)

      10/16/24 4:19:46 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    SEC Filings

    See more
    • SEC Form S-8 filed by BGM Group Ltd.

      S-8 - BGM Group Ltd. (0001779578) (Filer)

      6/3/25 4:31:34 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by BGM Group Ltd.

      6-K - BGM Group Ltd. (0001779578) (Filer)

      5/28/25 4:30:18 PM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by BGM Group Ltd.

      SCHEDULE 13G - BGM Group Ltd. (0001779578) (Subject)

      5/28/25 6:35:46 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BGM Group Announces Board Reshuffle: New Leadership Embarks on a Transformative Journey Amid Tech Revolution

      CHENGDU, China, Feb. 28, 2025 /PRNewswire/ -- BGM Group Ltd (NASDAQ:BGM) (the "Company" or "BGM") today announced changes to its board of directors, marking the Company's entry into a new phase of technological transformation and sustainable growth. Mr. Zhanchang Xin has tendered his resignation and will step down from his role as Chairman of the Company, effective March 1, 2025. He will be succeeded by Mr. Chen Xin, the current Chief Executive Officer of the Company, who will assume the position of Chairman. As the founder of the Company, Mr. Zhanchang Xin has, over the past six decades, has played a pivotal role in leading the Company through numerous challenges and milestones, including

      2/28/25 8:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BGM Group Establishes "Duxiaobao Management Committee" to Accelerate AI Strategy and Drive Intelligent Transformation in the Insurance Industry

      CHENGDU, China, Feb. 19, 2025 /PRNewswire/ -- BGM Group Ltd. (NASDAQ:BGM) announced the establishment of the "Duxiaobao Management Committee," which will be fully responsible for the management and decision-making of the "Duxiaobao" ecosystem. This move signifies BGM Group's strategic entry into the field of artificial intelligence, aiming to accelerate the transformation of the insurance industry into the smart era through AI technology. The Duxiaobao Management Committee consists of industry leaders such as Xin Chen, Li Yuqing, Ge Peng, Zhao Qi, Ren Yong, Li Jun, Zhou Xin, and Wang Hui. The committee has appointed Li Yuqing as the CEO of Duxiaobao, with Li Jun, Ren Yong, Zhou Xin, and Tan

      2/19/25 7:30:00 AM ET
      $BGM
      Biotechnology: Pharmaceutical Preparations
      Health Care